KRYS News and Press, Krystal Biotech Inc. From 03/29/19

The Company Krystal Biotech Inc. ( KRYS ) is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017 . It develops novel, "off-the-shelf", topical gene therapies for serious genetic skin diseases. Based on the strength ...

First EMA PRIME eligibility for Krystal Biotech Eligibility based on positive primary analysis of clinical and non clinical data to date PRIME Designation allows for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval PITTSBURGH, Ma...

Krystal Biotech (NASDAQ: KRYS ): FY GAAP EPS of -$0.97. More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1H 2019 Ancoris, a cGMP facility for clinical and commercial production of KB103, is operational following successful completion of...

New facility expected to meet all clinical and commercial development needs of lead program KB103 A second, larger cGMP facility expected to be completed in 2020 to meet all anticipated future pipeline production requirements PITTSBURGH, March 06, 2019 (GLOBE NEWSWIRE) -- Krystal...

PITTSBURGH, March 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (Krystal) (NASDAQ: KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, announced that Julian S. Gangolli has been elected to Krystal’s Board of Dir...

PITTSBURGH, March 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman ...

Overview Of Krystal Biotech I first introduced Krystal Biotech ( KRYS ) as a long idea several months ago after they released compelling data in dystrophic epidermolysis bullosa (DEB). After doing a deep dive, I published a more lengthy research piece explaining why I believed this compa...

PITTSBURGH, Feb. 22, 2019 (GLOBE NEWSWIRE) --   Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chai...

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...